N John Bosomworth1. 1. Department of Family Medicine, University of British Columbia, Vancouver, BC, Canada. john.bosomworth@interiorhealth.ca
Abstract
OBJECTIVE: To review the 2009 Canadian Cardiovascular Society guidelines and provide practical recommendations for physicians. SOURCES OF INFORMATION: Initial review of the references provided with the guidelines led to a search of the PubMed, ACP Journal Club, and Cochrane databases using the key words primary prevention and statin for English language clinical trials, randomized controlled trials, meta-analyses, and reviews conducted with human participants. References from appropriate retrieved articles were also reviewed. MAIN MESSAGE: The guidelines outline low-density lipoprotein cholesterol (LDL-C) thresholds and targets to inform optimal use of statins in the primary prevention of cardiovascular disease (CVD). Family history of CVD and levels of high-sensitivity C-reactive protein (hsCRP) are risk modifiers in calculating the risk score with the new recommendations. An electronic calculator has been developed to facilitate increased uptake of these guidelines. Large numbers of asymptomatic people, particularly the elderly, will become eligible for statin therapy according to these new guidelines. Poor uptake by physicians and patients might result from the need for repeated testing of hsCRP and LDL-C levels in people who do not perceive themselves to be ill. Controversy persists concerning the role of hsCRP in the reclassification of CVD risk, and the concept of treating LDL-C to target has never been tested as an independent variable in a randomized trial. As two-thirds of the LDL-C lowering achieved by a statin occurs at the initial dose, it might be possible to achieve considerable CVD risk reduction for those at risk by treating initially with a mid-dose statin without LDL-C follow-up. CONCLUSION: A simplified approach might appeal to patients or physicians who find current guidelines too complex, cumbersome, or costly. Success in getting high-risk patients to take statins is key to achieving improved CVD mortality reduction.
OBJECTIVE: To review the 2009 Canadian Cardiovascular Society guidelines and provide practical recommendations for physicians. SOURCES OF INFORMATION: Initial review of the references provided with the guidelines led to a search of the PubMed, ACP Journal Club, and Cochrane databases using the key words primary prevention and statin for English language clinical trials, randomized controlled trials, meta-analyses, and reviews conducted with humanparticipants. References from appropriate retrieved articles were also reviewed. MAIN MESSAGE: The guidelines outline low-density lipoprotein cholesterol (LDL-C) thresholds and targets to inform optimal use of statins in the primary prevention of cardiovascular disease (CVD). Family history of CVD and levels of high-sensitivity C-reactive protein (hsCRP) are risk modifiers in calculating the risk score with the new recommendations. An electronic calculator has been developed to facilitate increased uptake of these guidelines. Large numbers of asymptomatic people, particularly the elderly, will become eligible for statin therapy according to these new guidelines. Poor uptake by physicians and patients might result from the need for repeated testing of hsCRP and LDL-C levels in people who do not perceive themselves to be ill. Controversy persists concerning the role of hsCRP in the reclassification of CVD risk, and the concept of treating LDL-C to target has never been tested as an independent variable in a randomized trial. As two-thirds of the LDL-C lowering achieved by a statin occurs at the initial dose, it might be possible to achieve considerable CVD risk reduction for those at risk by treating initially with a mid-dose statin without LDL-C follow-up. CONCLUSION: A simplified approach might appeal to patients or physicians who find current guidelines too complex, cumbersome, or costly. Success in getting high-risk patients to take statins is key to achieving improved CVD mortality reduction.
Authors: Yola Moride; Robert A Hegele; Anatoly Langer; Ruth McPherson; David B Miller; Stéphane Rinfret Journal: Can J Cardiol Date: 2008-04 Impact factor: 5.223
Authors: Rodney A Hayward; Harlan M Krumholz; Donna M Zulman; Justin W Timbie; Sandeep Vijan Journal: Ann Intern Med Date: 2010-01-19 Impact factor: 25.391
Authors: J J Brugts; T Yetgin; S E Hoeks; A M Gotto; J Shepherd; R G J Westendorp; A J M de Craen; R H Knopp; H Nakamura; P Ridker; R van Domburg; J W Deckers Journal: BMJ Date: 2009-06-30
Authors: Ralph B D'Agostino; Ramachandran S Vasan; Michael J Pencina; Philip A Wolf; Mark Cobain; Joseph M Massaro; William B Kannel Journal: Circulation Date: 2008-01-22 Impact factor: 29.690
Authors: J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard Journal: N Engl J Med Date: 1995-11-16 Impact factor: 91.245
Authors: Colin R Dormuth; Sebastian Schneeweiss; Alan M Brookhart; Greg Carney; Ken Bassett; Stephen Adams; James M Wright Journal: Open Med Date: 2008-08-12
Authors: Amanda S Hinerman; Emma J M Barinas-Mitchell; Samar R El Khoudary; Anita P Courcoulas; Abdus S Wahed; Wendy C King Journal: Surg Obes Relat Dis Date: 2020-04-19 Impact factor: 4.734
Authors: Daniel Mølager Christensen; Matthew Phelps; Thomas Gerds; Morten Malmborg; Anne-Marie Schjerning; Jarl Emanuel Strange; Mohamad El-Chouli; Lars Bruun Larsen; Emil Fosbøl; Lars Køber; Christian Torp-Pedersen; Suneela Mehta; Rod Jackson; Gunnar Gislason Journal: Eur Heart J Open Date: 2021-08-02
Authors: Miguel A Salinero-Fort; Francisco J San Andrés-Rebollo; Carmen de Burgos-Lunar; Paloma Gómez-Campelo; Rosa M Chico-Moraleja; Ana López de Andrés; Rodrigo Jiménez-García Journal: PLoS One Date: 2015-04-09 Impact factor: 3.240
Authors: Seungwon Lee; Bing Li; Elliot A Martin; Adam G D'Souza; Jason Jiang; Chelsea Doktorchik; Danielle A Southern; Joon Lee; Natalie Wiebe; Hude Quan; Cathy A Eastwood Journal: CJC Open Date: 2020-12-27
Authors: Miguel Á Salinero-Fort; Francisco Javier San Andrés-Rebollo; Carmen de Burgos-Lunar; Francisco Jesús Arrieta-Blanco; Paloma Gómez-Campelo Journal: PLoS One Date: 2013-10-17 Impact factor: 3.240